71 Participants Needed

Text Messaging Support for HIV

CJ
SM
Overseen BySean M Murphy, PhD
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: Friends Research Institute, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to identify the most effective and cost-efficient methods to help transgender women living with HIV manage their health. It tests three approaches: one group receives support through text messages ("Text Me, Alexis!"), another through peer health navigation (one-on-one guidance), and the last group receives both. Ideal participants are transgender women diagnosed with HIV who have not recently visited an HIV care clinic, are not currently taking HIV medication, or have difficulty consistently taking their medication. Participants must be able to receive daily text messages on their phone or email. As an unphased trial, this study provides a unique opportunity to contribute to innovative strategies for improving health management.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on supporting HIV care through text messaging and peer navigation, so it's likely you can continue your current medications.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that text messaging programs like "Text Me, Alexis!" are generally safe and well-received. Studies on similar programs, such as "Text Me, Girl!", found them effective in improving HIV care without significant side effects. Participants receive daily text messages about HIV care and support, and users have responded positively to this approach.

For the Peer Health Navigation (PHN) component, research has proven it safe and effective. Previous studies have demonstrated that PHN helps people stay engaged in HIV care and adhere to their medication without negative effects. Combining PHN with text messaging has also been studied, yielding positive results in supporting people with HIV.

Overall, both the text messaging and peer navigation components have proven safe based on past use in similar situations.12345

Why are researchers excited about this trial?

Researchers are excited about these treatments because they offer innovative support methods for managing HIV. Unlike standard antiretroviral therapies that focus solely on medication, "Text Me, Alexis!" uses daily text messaging to provide encouragement, education, and reminders, helping people stay on track with their care. The PHN and SMS combination adds a personalized touch with peer health navigation, addressing individual barriers and providing tailored support. This approach leverages technology and human connection, aiming to improve adherence and overall health outcomes for people living with HIV.

What evidence suggests that this trial's treatments could be effective for advancing trans women living with HIV to full viral suppression?

Research has shown that text messaging can significantly assist people living with HIV. Studies have found that sending text messages improves medication adherence and helps lower viral loads. In this trial, participants in the "Text Me, Alexis!" program will receive daily motivational and educational texts, which have shown promise in helping young trans women with HIV remain engaged in their care.

Another group in this trial will receive Peer Health Navigation (PHN), which has proven effective in maintaining low viral levels by offering personalized support. Peer navigators help overcome personal challenges to care, keeping individuals on track with their treatment plans.

A third group will receive a combination of PHN and text messaging, potentially offering the best of both approaches. This combination might enhance medication adherence and reduce viral levels by providing both personal support and regular text reminders.12678

Who Is on the Research Team?

CJ

Cathy J Reback, PhD

Principal Investigator

Friends Research Institute, Inc.

SM

Sean M Murphy, PhD

Principal Investigator

Weill Medical College of Cornell University

Are You a Good Fit for This Trial?

This trial is for trans women living with HIV/AIDS. Participants should be interested in interventions aimed at achieving full viral suppression. The study excludes individuals who do not meet the inclusion criteria set by the researchers, which are not specified here.

Inclusion Criteria

I identify as a transgender woman.
Verified HIV positive status
Ability to receive daily text messages on either a personal cell phone or via an email account
See 1 more

Exclusion Criteria

I am under 18 years old.
HIV negative status
Does not have the ability to receive daily text messages on either a personal cell phone or via an email account
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Peer Health Navigation (PHN), SMS text messaging, or a combination of both for 90 days

12 weeks
Unlimited PHN sessions, daily SMS messages

Follow-up

Participants are monitored for safety and effectiveness after treatment with assessments at 3, 6, 12, and 18 months post-enrollment

18 months
Assessments at 3, 6, 12, and 18 months

What Are the Treatments Tested in This Trial?

Interventions

  • Text Me, Alexis!
Trial Overview 'Text Me, Alexis!' is a study testing three approaches to help trans women with HIV reach full viral suppression: Peer Health Navigation (PHN), text messaging (SMS), or a combination of both PHN and SMS over three months.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Group I: Simple Message System (SMS [text messaging])Experimental Treatment1 Intervention
Group II: Peer Health Navigation (PHN)Experimental Treatment1 Intervention
Group III: PHN and SMSExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Friends Research Institute, Inc.

Lead Sponsor

Trials
60
Recruited
22,500+

Weill Medical College of Cornell University

Collaborator

Trials
1,103
Recruited
1,157,000+

Published Research Related to This Trial

The Connect4Care (C4C) text messaging intervention did not significantly improve virologic suppression rates among HIV patients after 12 months, with 48.8% in the intervention group compared to 45.8% in the control group.
However, newly diagnosed patients showed higher suppression rates (78.3% vs 45.3%), and the study suggests that patient engagement through responses to text messages may be an important factor in achieving better health outcomes.
A Randomized Controlled Trial of a Text Messaging Intervention to Promote Virologic Suppression and Retention in Care in an Urban Safety-Net Human Immunodeficiency Virus Clinic: The Connect4Care Trial.Christopoulos, KA., Riley, ED., Carrico, AW., et al.[2022]
Text messaging interventions have been shown to effectively improve adherence to antiretroviral therapy and increase appointment attendance among people living with HIV, based on a systematic review of nine high-quality reviews involving 37 studies across 19 countries.
There are significant knowledge gaps regarding long-term outcomes and patient satisfaction with text messaging interventions, indicating a need for further research to fully understand their impact and potential in managing other chronic diseases.
Mobile phone text messaging interventions for HIV and other chronic diseases: an overview of systematic reviews and framework for evidence transfer.Mbuagbaw, L., Mursleen, S., Lytvyn, L., et al.[2022]
Mobile phones and SMS technology present a promising opportunity to improve HIV self-management and healthcare outcomes for people living with HIV, transforming the disease into a manageable condition.
An effective SMS-based intervention should focus on interactivity, frequency, timing, and message tailoring to enhance medication adherence and promote positive health behaviors, ultimately leading to better clinical outcomes.
Beyond reminders: a conceptual framework for using short message service to promote prevention and improve healthcare quality and clinical outcomes for people living with HIV.Coomes, CM., Lewis, MA., Uhrig, JD., et al.[2022]

Citations

Comparative- and Cost-Effectiveness Research ...Interventions including PHN have been shown to be efficacious in improving rates of HIV care engagement, ART adherence, and viral suppression among transgender ...
A Novel Adaptation of Peer Health Navigation and ...The Alexis Project was a combined Peer Health Navigation (PHN) and Contingency Management (CM) intervention that targeted HIV milestones associated with ...
and Cost-effectiveness Research Determining the Optimal ...text messaging arm will receive a combined PHN and SMS text message intervention. The desired outcome of Text Me, Alexis! is viral suppression ...
Optimal Intervention to Full Viral Suppression: Text Me, ...Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal (considering effectiveness and cost-effectiveness) ...
HIV Care Continuum Interventions Transgender WomenHowever, due to the intensity of PHN, some transgender women may prefer a lower-intensity intervention such as SMS text messaging to deliver gender-affirming, ...
Adherence to the Continuum of Care | NIHIt is estimated that only approximately 69% of people with complete data were virologically suppressed within 6 months of diagnosis. This low ...
Effect of mobile text messages on antiretroviral medication ...We investigated whether a daily text messaging intervention improves ART adherence and retention in early HIV care in PHIV in a south Florida ...
Mobile phone text messaging for promoting adherence to ...In the trial comparing only short weekly messages to standard care, text messaging was associated with lower risk of non‐adherence at 12 months, and with the ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security